The MedTech sector faces mounting risks from tariffs, supply chain fragility, and geopolitical uncertainty. Canada, heavily reliant on U.S. trade, is especially exposed, with 74% of exports going south and 40% of imports sourced from the U.S.. Retaliatory tariffs raise costs for surgical, imaging, and implantable devices, while reliance on Chinese rare earths and semiconductors adds vulnerability. IQVIA recommends short-term strategies like scenario analysis, supply chain diversification, and financial planning, alongside long-term localization, reshoring to Mexico/Canada, and digital innovation. Building resilience through regulatory agility, market insights, and advanced logistics is key.

Join for free to read